DJO posted March 2019 revenue of USD $37.2MM, +17.4% vs. March 2018.
- Revenue for 1Q19 is for March only, as Colfax completed the acquisition of DJO on February 22, 2019
- Growth was driven by sales of joint replacement products, while prevention and rehab (categorized in our “Other” segment) remain on track with improvement plans
- DJO launched six new products in the first quarter, including the ADAPTABLE Surgical Arm for hip replacement surgery
- Colfax leadership believes that the mechanization of implant procedures offered by products like ADAPTABLE is an important area of differentiation
- All key DJO leaders have been through Colfax’s leadership training, and going forward will drive more strict operating discipline through monthly reviews and “aggressive” daily management
ORTHOWORLD estimates segment sales and growth on an as-reported basis. The Other segment includes DJO’s Recovery Sciences. ($MM)
| Mar-19 | Mar-18 | $ Chg | % Chg |
| Joint Reconstruction | $29.1 | $24.5 | $4.7 | 19.0% |
| Knees | $7.7 | $6.4 | $1.3 | 19.7% |
| Hips | $6.5 | $5.5 | $1.0 | 18.1% |
| Extremities | $14.9 | $12.5 | $2.4 | 19.1% |
| Other | $8.0 | $7.2 | $0.8 | 11.8% |
| Total | $37.2 | $31.7 | $5.5 | 17.4% |
Sources: Colfax Corp.; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Copy to clipboard 
